+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Overview: Eligard

  • PDF Icon

    Drug Pipelines

  • 9 Pages
  • January 2018
  • Region: Global
  • Citeline
  • ID: 4462183
Drug Overview

Eligard (leuprolide; Astellas/Tolmar Pharmaceuticals) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare." Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration.

Table of Contents

Product Profiles
Eligard: Prostate cancer

List of Figures
Figure 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26